
==== Front
Neurooncol Adv
Neurooncol Adv
noa
Neuro-Oncology Advances
2632-2498
Oxford University Press US

10.1093/noajnl/vdae090.121
vdae090.121
Final Category: Supportive Care, Palliative Care and QOL
AcademicSubjects/MED00300
AcademicSubjects/MED00310
QSPC-03 PATIENT-REPORTED QUALITY OF LIFE AFTER UNDERGOING STEREOTACTIC RADIOSURGERY FOR BRAIN METASTASES: A PROSPECTIVE ASSESSMENT UTILIZING A U.S. NATIONAL REGISTRY
Pham BA Duy University of Virginia School of Medicine, Charlottesville, VA, USA

Sheehan Darrah University of Virginia School of Engineering and Applied Sciences, Charlottesville, VA, USA

Sheehan Kimball University of Virginia School of Engineering and Applied Sciences, Charlottesville, VA, USA

MBBS Konstantinos Katsos Neuro-Informatics Laboratory, Mayo Clinic, Rochester, MN, USA
Department of Neurologic Surgery, Mayo Clinic, Rochester, MN, USA

MD Camilo Fadul University of Virginia School of Medicine, Department of Neurology, Charlottesville, VA, USA

MD Jason Sheehan University of Virginia School of Medicine, Department of Neurologic Surgery, Charlottesville, VA, USA

8 2024
02 8 2024
02 8 2024
6 Suppl 1 2024 SNO/ASCO CNS Metastases Conference i37i37
© The Author(s) 2024. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology.
2024
https://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com

Abstract

Patients with brain metastases (BMETS) frequently emphasize the impact on quality of life (QOL) over prolongation of life at the time of making treatment decisions. Thus, it is critical to evaluate patient-reported health utility scores after treatment of BMETS. Stereotactic surgery (SRS) is becoming the most frequent treatment modality. The objective of this study was to determine the changes in the EuroQol- 5 Dimension (EQ-5D) in patients with BMETS treated with SRS. The NPA SRS Registry is a multi-institutional collaboration prospectively collecting information from patients undergoing SRS since 2017. We queried the registry for the results of the baseline and follow-up EQ-5D questionnaire, with a utility index score given based on the patient’s responses for five domains: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The cohort included 522 cases treated with SRS between 2017 and 2023; 264 (47.8%), 197 (35.7%), and 91 (16.5%) had 1, 2-4, and 5-14 metastases, respectively. The mean EQ-5D score at the time of SRS was 0.551 (SD=0.443). At the last follow-up after SRS, 107 (34.0%) patients indicated improvement from their EQ-5D baseline while 51 (16.2%) were stable. The score decreased in 113 patients (35.9%) while 44 (13.9%) showed mixed changes (i.e., domain sub-scores both increased and decreased). For mobility, usual activities, pain/discomfort, and anxiety/depression domains patients experienced similar rates of improvement (21.0%-22.5%). In the self-care domain, 32 (10.2%) patients reported improvement, 232 (73.7%) reported no change and 89 (28.3%) had worsening scores. Our study provided the first longitudinal prospective real-world data using the EQ-5D, a health utility tool, in patients with BMETS treated with SRS. In more than half of the cases, the patients reported improved or stable EQ-5D scores over time after treatment. Factors independent of treatment that may prompt worsening QOL following SRS are being identified and will be presented.
==== Body
pmc
